Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites
Background: Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy. Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) constitute 55% of new nhl cases and are initially treated with rituximab-based chemoimmunotherapy. Relative to intravenous (IV) rituximab, a subcutaneous (SC) formulation approved in 2016 has comparable pharmacokinetics, efficacy, and safety, and a greatly reduced administration time; it is also preferred by patients. The objective of the present study was to estimate the effect (on systemic therapy suite time and on the costs of drug acquisition and administration) of implementing SC rituximab in the initial chemoimmunotherapy for FL and DLBCL over 3 years in the Canadian market.
Acknowledgments: Shainur Premji MSc of the University of Calgary and Marg Hux MSc of Medlior Health Outcomes Research Ltd. provided economic consulting, modelling, and writing. Dominika Dabrowski MSc of DKDA Consulting Inc. conducted the expert interviews. Tara Cowling MSc of Medlior Health Outcomes Research Ltd. provided writing and editorial assistance.
Year of Publication: 2018
Authors: D.A. Stewart, J.S. Boudreault, B. Maturi, D. Boras, R. Foley